Vital Therapies, Inc. — Form 10-Q Summary
Filing identity: The request metadata names IMMUNIC, INC., but the supplied filing is for Vital Therapies, Inc. This summary reflects the filing provided. Reporting period ended September 30, 2016; filed November 3, 2016.
Business context and reporting period
Vital Therapies is a clinical-stage biotherapeutics company developing ELAD, an extracorporeal cell-based therapy for acute liver failure. It had no revenue from planned principal operations. Its sole product candidate was being evaluated in the Phase 3 VTL-308 trial for severe acute alcoholic hepatitis (sAAH). After VTI-208 failed to meet its primary and secondary endpoints in 2015, the company discontinued VTI-210 and VTI-212 and refocused resources on VTL-308.
Financial performance and position
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $7.5 million | $9.6 million | $21.2 million | $32.9 million |
| General and administrative expense | $2.8 million | $2.7 million | $8.3 million | $9.3 million |
| Total operating expenses | $10.2 million | $12.3 million | $29.4 million | $42.2 million |
| Net loss | $10.2 million | $12.3 million | $29.2 million | $42.2 million |
| Basic and diluted loss per share | $0.32 | $0.51 | $0.94 | $1.76 |
Margins are not meaningful because the company reported no operating revenue. At September 30, 2016, cash and cash equivalents were $68.1 million, restricted cash was $18,000, total current assets were $69.5 million, and total current liabilities were $4.6 million. Total liabilities were approximately $4.7 million; the filing reports no debt balance. Stockholders’ equity was $67.8 million, and accumulated deficit was $232.1 million.
For the first nine months of 2016, operating cash use was $26.7 million, investing activities provided $80,000, and financing activities provided $11.3 million. Cash and cash equivalents declined $15.3 million from year-end 2015. Financing included ATM stock sales and a private placement. The company reported 31.9 million common shares outstanding at September 30 and 32.1 million at October 31, 2016.
Changes versus prior comparable period
- Nine-month operating expenses fell 30% year over year, led by a $11.8 million reduction in R&D, principally because VTI-208 and the other discontinued trials no longer incurred comparable costs. Lower G&A also reflected 2015 workforce reductions and reduced consulting and other costs.
- Q3 R&D decreased 23% year over year, partly offset by VTL-308 site-opening and enrollment costs. Q3 G&A rose 3%, including higher incentive accruals and stock-based compensation.
- Nine-month operating cash use improved from $40.7 million to $26.7 million. The company raised $11.0 million gross through the ATM during the first nine months and completed a $700,000 private placement.
Outlook, risks, and notable items
- Management estimated that cash at September 30, together with approximately $602,000 net ATM proceeds received in October, would fund operations through the first quarter of 2018, assuming limited BLA-related work and no significant commercial infrastructure buildout. It anticipated raising additional funds before VTL-308 topline results, then expected in mid-2018.
- As of October 31, 2016, VTL-308 had 19 enrolled subjects and 31 open sites; the company expected at least 150 subjects at about 40 sites. The trial is event-driven and designed to continue until at least 55 events occur. Enrollment timing, trial outcomes, and regulatory requirements could change costs and funding needs.
- The prior Phase 3 VTI-208 trial failed its primary and secondary endpoints. VTL-308 relies on analyses of subsets from that trial; success is uncertain, and regulators could require another confirmatory trial even if VTL-308 meets its endpoint.
- The company warned that it will need additional capital and has no committed external funding source. Equity financing may dilute shareholders; financing may not be available on acceptable terms. Failure to raise funds could force delays, reductions, or termination of development activities.
- Other material risks include dependence on one product candidate, clinical and manufacturing risks, regulatory approval and reimbursement uncertainty, reliance on single-source suppliers for some components, and potential competition. The company reported that the securities class action was dismissed with prejudice as to the plaintiff on August 9, 2016.
- Management said disclosure controls were effective as of September 30, 2016, and reported no material change in internal control during the period. The filing also notes prior control deficiencies and completed remediation efforts.
Important facts for investors to verify
- Whether VTL-308 enrollment and event accrual remain on schedule and whether the trial’s narrow eligibility criteria support timely recruitment.
- Current cash burn and runway versus management’s first-quarter 2018 estimate, including the timing and terms of future financing.
- Whether VTL-308 results can support regulatory submissions or whether additional pivotal or confirmatory studies will be required.
- Potential dilution from ATM and other shelf offerings, stock options, and warrants.
- Ongoing clinical, manufacturing, supplier, regulatory, reimbursement, and intellectual-property risks, including any material developments after the filing date.